Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Zollinger-Ellison Syndrome 1Vomiting 1Stomach Neoplasms 1Prostatic Neoplasms 1Ototoxicity 1Osteosarcoma 1Neoplasm Metastasis 1Helicobacter Infections 1Gastritis, Atrophic 1Gastrinoma 1Breast Neoplasms 1Advanced Solid Tumours 1

Interventions

Capecitabine 3Trastuzumab 2Temozolomide 2Streptozocin 2Leucovorin 2Fluorouracil 2vatalanib 1tipifarnib 1regorafenib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Pantoprazole 1Oxaliplatin 1Omeprazole 1Octreotide 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Gefitinib 1Floxuridine 1Fentanyl 1Everolimus 1Doxorubicin 1Cisplatin 1Bortezomib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastrinoma × Pantoprazole × Clear all
NCT00001191 2017-07-02

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

National Institutes of Health Clinical Center (CC)

Phase 2 Completed

Zollinger-Ellison Syndrome, Gastrinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡